Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02777385
Title Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Pittsburgh

larynx cancer

oral squamous cell carcinoma

oropharynx cancer

head and neck squamous cell carcinoma

hypopharynx cancer


Cisplatin + Pembrolizumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.